CINCINNATI / Jan 09, 2025 / Business Wire / Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 43rd Annual JPMorgan Healthcare Conference on Tuesday, January 14, 2024, at approximately 10:30 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA.
The presentation will be webcast live and can be accessed through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available approximately three hours after the live presentation and will be accessible for 90 days.
Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.
Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.
Last Trade: | US$562.00 |
Daily Change: | 0.66 0.12 |
Daily Volume: | 94,246 |
Market Cap: | US$8.420B |
November 05, 2024 October 29, 2024 July 24, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load